Repatha: 'Repatha shows powerful LDL-C reduction in patients with atherosclerotic cardiovascular disease'

As Amgen's Repatha, a low-density lipoprotein cholesterol (LDL-C) treatment, marks its seventh year since its introduction in Korea in 2017, the company held a press conference to present significant advancements in cardiovascular disease management and the role of Repatha in the field.Song Mi-young